A mutant library approach to identify improved meningococcal factor H binding protein vaccine antigens

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Konar, Monica ^a   Rossi, Raffaella ^a   Walter, Helen ^a,b   Pajon, Rolando ^a   Beernink, Peter T ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

^b MILLS COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; COMPLEMENT FACTOR H; FACTOR H BINDING PROTEIN; MENINGOCOCCUS VACCINE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VIRULENCE FACTOR; BACTERIAL PROTEIN; COMPLEMENT FACTOR H, HUMAN; IMMOBILIZED PROTEIN; MUTANT PROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN DETECTION; ARTICLE; BACTERIAL CELL; BACTERIAL STRAIN; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; IMMUNOGENICITY; MOLECULAR CLONING; MOLECULAR LIBRARY; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; VACCINATION; ANIMAL; ANTIBODY PRODUCTION; DIFFERENTIAL SCANNING CALORIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LIBRARY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR MODEL; MUTATION; PROTEIN CONFORMATION; PROTEIN STABILITY; SERUM; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE; TRANSGENIC MOUSE;

ESCHERICHIA COLI; MUS MUSCULUS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CALORIMETRY, DIFFERENTIAL SCANNING; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE LIBRARY; HUMANS; IMMOBILIZED PROTEINS; MENINGOCOCCAL VACCINES; MICE, TRANSGENIC; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; MUTATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STABILITY; RECOMBINANT PROTEINS; SERUM; SURFACE PLASMON RESONANCE;

EID: 84936792256     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0128185     Document Type: Article

References (45)

1. Meri S, Jordens M, Jarva H. Microbial complement inhibitors as vaccines. Vaccine. 2008; 26 Suppl 8: I113-7. Epub 2009/04/24. PMID: 19388175.
2. Excler JL, Tomaras GD, Russell ND. Novel directions in HIV-1 vaccines revealed from clinical trials. Current opinion in HIV and AIDS. 2013; 8(5):421-31. doi: 10.1097/COH.0b013e3283632c26 PMID: 23743791.
3. Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A, et al. Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine. 2007; 25(3):450-7. Epub 2006/10/21. doi: 10.1016/j.vaccine.2006.08.001 PMID: 17052819.
4. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature. 1998; 393(6686):705-11. doi: 10.1038/31514 PMID: 9641684.
5. Vandeputte-Rutten L, Bos MP, Tommassen J, Gros P. Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem. 2003; 278 (27):24825-30. doi: 10.1074/jbc.M302803200 PMID: 12716881.
6. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010; 50(2):184-91. Epub 2009/12/17. doi: 10.1086/649209 PMID: 20001736.
7. Marshall HS, Richmond PC, Nissen MD, Jiang Q, Anderson AS, Jansen KU, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial. Pediatr Infect Dis J. 2012; 31(10):1061-8. Epub 2012/06/22. doi: 10.1097/INF.0b013e31826327e4 PMID: 22718089.
8. Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010; 51(10):1127-37. Epub 2010/10/20. doi: 10.1086/656741 PMID: 20954968.
9. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, Eisen JA, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science. 2000; 287(5459):1809-15. Epub 2000/03/10. 8338 [pii]. PMID: 10710307.
10. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006; 177(1):501-10. Epub 2006/06/21. 177/1/501 [pii]. PMID: 16785547; PubMed Central PMCID: PMC2248442.
11. Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect Immun. 2009; 77(2):764-9. Epub 2008/12/03. IAI.01191-08 [pii] doi: 10.1128/IAI.01191-08 PMID: 19047406; PubMed Central PMCID: PMC2632036.
12. Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM. Heterogeneity in rhesus macaque complement Factor H binding to meningococcal Factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines. Clin Vaccine Immunol. 2014; 21(11):1505-11. doi: 10.1128/CVI.00517-14 PMID: 25185576.
13. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003; 197(6):789-99. Epub 2003/03/19. doi: 10.1084/jem.20021911 jem.20021911 [pii]. PMID: 12642606; PubMed Central PMCID: PMC2193853.
14. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004; 72(4):2088-100. Epub 2004/03/25. PMID: 15039331; PubMed Central PMCID: PMC375149.
15. Jiang HQ, Hoiseth SK, Harris SL, McNeil LK, Zhu D, Tan C, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010; 28(37):6086-93. Epub 2010/07/14. S0264-410X(10)00924-2 [pii] doi: 10. 1016/j.vaccine.2010.06.083 PMID: 20619376.
16. Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, et al. Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys. Vaccine. 2011; 29(29-30):4728-34. doi: 10.1016/j. vaccine.2011.04.095 PMID: 21571025; PubMed Central PMCID: PMC3114263.
17. Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT. Binding of complement Factor H decreases protective anti-FHbp antibody responses of infant rhesus macaques immunized with a meningococcal serogroup B vaccine. J Infect Dis 101093/infdis/jiv081. 2015. doi: 10.1093/infdis/jiv081 PMID: 25676468.
18. Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garces-Sanchez M, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial. The Lancet infectious diseases. 2012; 12(8):597-607. Epub 2012/05/10. doi: 10.1016/S1473-3099(12)70087-7 PMID: 22569484.
19. Richmond PC, Nissen MD, Marshall HS, Lambert SB, Roberton D, Gruber WC, et al. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial. Vaccine. 2012; 30(43):6163-74. Epub 2012/08/ 09. doi: 10.1016/j.vaccine.2012.07.065 PMID: 22871351.
20. Snape MD, Dawson T, Oster P, Evans A, John TM, Ohene-Kena B, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010; 29(11):e71-9. Epub 2010/09/17. doi: 10.1097/INF.0b013e3181f59f6d PMID: 20844462.
21. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine. 2011; 29(5):1072-81. Epub 2010/12/07. S0264-410X(10)01708-1 [pii] doi: 10.1016/j.vaccine.2010.11. 064 PMID: 21130753.
22. Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, et al. A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011; 186(6):3606-14. Epub 2011/02/18. jimmunol.1003470 [pii] doi: 10.4049/ jimmunol.1003470 PMID: 21325619.
23. Schneider MC, Prosser BE, Caesar JJ, Kugelberg E, Li S, Zhang Q, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009; 458(7240):890-3. Epub 2009/02/20. nature07769 [pii] doi: 10.1038/nature07769 PMID: 19225461; PubMed Central PMCID: PMC2670278.
24. Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM. The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein. PLoS Pathog. 2012; 8(5):e1002688. Epub 2012/05/17. doi: 10.1371/journal. ppat.1002688 PMID: 22589720; PubMed Central PMCID: PMC3349754.
25. Pajon R, Beernink PT, Granoff DM. Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H. Infect Immun. 2012; 80(8):2667-77. Epub 2012/05/23. doi: 10.1128/IAI.00103-12 PMID: 22615247; PubMed Central PMCID: PMC3434564.
26. Rossi R, Granoff DM, Beernink PT. Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice. Vaccine. 2013; 31(46):5451-7. doi: 10.1016/j.vaccine.2013.08.099 PMID: 24035433.
27. Johnson S, Tan L, van der Veen S, Caesar J, Goicoechea De Jorge E, Harding RJ, et al. Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog. 2012; 8(10):e1002981. doi: 10.1371/journal.ppat.1002981 PMID: 23133374; PubMed Central PMCID: PMC3486911.
28. van der Veen S, Johnson S, Jongerius I, Malik T, Genovese A, Santini L, et al. Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun. 2014; 82(3):1157-63. doi: 10.1128/IAI.01183-13 PMID: 24379280; PubMed Central PMCID: PMC3958001.
29. Vu DM, Pajon R, Reason DC, Granoff DM. A broadly cross-reactive monoclonal antibody against an epitope on the N-terminus of meningococcal fHbp. Scientific reports. 2012; 2:341. Epub 2012/03/31. doi: 10.1038/srep00341 PMID: 22461972; PubMed Central PMCID: PMC3314305.
30. Giuliani MM, Santini L, Brunelli B, Biolchi A, Arico B, Di Marcello F, et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun. 2005; 73(2):1151-60. Epub 2005/01/25. doi: 10.1128/IAI.73.2.1151-1160.2005 PMID: 15664958; PubMed Central PMCID: PMC546939.
31. Giuntini S, Reason DC, Granoff DM. Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding. Infect Immun. 2011; 79(9):3751-9. Epub 2011/06/29. IAI.05182-11 [pii] doi: 10.1128/IAI.05182-11 PMID: 21708990; PubMed Central PMCID: PMC3165461.
32. Konar M, Granoff DM, Beernink PT. Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines. J Infect Dis. 2013; 208(4):627-36. doi: 10.1093/infdis/jit239 PMID: 23715659; PubMed Central PMCID: PMC3719908.
33. Beernink PT, Granoff DM. Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines. Infect Immun. 2008; 76(6):2568-75. Epub 2008/03/26. IAI.00033-08 [pii] doi: 10.1128/IAI.00033-08 PMID: 18362128; PubMed Central PMCID: PMC2423104.
34. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis. 2009; 199(9):1360-8. Epub 2009/03/24. doi: 10.1086/597806 PMID: 19302008; PubMed Central PMCID: PMC2914608.
35. Froholm LO, Caugant DA, Holten E, Hoiby EA, Rosenqvist E, Wedege E. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH annals. 1991; 14(2):139-43; discussion 44-6. PMID: 1812428.
36. Piet JR, Huis in 't Veld RA, van Schaik BD, van Kampen AH, Baas F, van de Beek D, et al. Genome sequence of Neisseria meningitidis serogroup B strain H44/76. J Bacteriol. 2011; 193(9):2371-2. Epub 2011/03/08. JB.01331-10 [pii] doi: 10.1128/JB.01331-10 PMID: 21378179.
37. Pajon R, Beernink PT, Harrison LH, Granoff DM. Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates. Vaccine. 2010; 28(9):2122-9. Epub 2010/01/02. S0264-410X(09)01931-8 [pii] doi: 10.1016/j.vaccine.2009.12. 027 PMID: 20044056; PubMed Central PMCID: PMC2830318.
38. Costa I, Pajon R, Granoff DM. Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding. mBio. 2014; 5(5):e01625-14. doi: 10.1128/ mBio.01625-14 PMID: 25161192; PubMed Central PMCID: PMC4173785.
39. Cendron L, Veggi D, Girardi E, Zanotti G. Structure of the uncomplexed Neisseria meningitidis factor H-binding protein fHbp (rLP2086). Acta Crystallogr Sect F Struct Biol Cryst Commun. 2011; 67(Pt 5):531-5. Epub 2011/05/06. S1744309111006154 [pii] doi: 10.1107/S1744309111006154 PMID: 21543855; PubMed Central PMCID: PMC3087634.
40. Welsch JA, Rossi R, Comanducci M, Granoff DM. Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol. 2004; 172(9):5606-15. Epub 2004/04/22. PMID: 15100304.
41. Beernink PT, Welsch JA, Bar-Lev M, Koeberling O, Comanducci M, Granoff DM. Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor H-binding protein. Infect Immun. 2008; 76(9):4232-40. Epub 2008/07/02. doi: 10.1128/IAI.00367-08IAI.00367-08 [pii]. PMID: 18591239; PubMed Central PMCID: PMC2519416.
42. Beernink PT, LoPasso C, Angiolillo A, Felici F, Granoff D. A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol. 2009; 46(8-9):1647-53. Epub 2009/03/17. S0161-5890(09)00094-7 [pii] doi: 10.1016/j. molimm.2009.02.021 PMID: 19286260; PubMed Central PMCID: PMC2673115.
43. Scarselli M, Cantini F, Santini L, Veggi D, Dragonetti S, Donati C, et al. Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis. J Mol Biol. 2009; 386(1):97-108. Epub 2008/12/23. S0022-2836(08)01494-0 [pii] doi: 10.1016/j.jmb.2008.12.005 PMID: 19100746.
44. Mascioni A, Bentley BE, Camarda R, Dilts DA, Fink P, Gusarova V, et al. Structural basis for the immunogenic properties of the meningococcal vaccine candidate LP2086. J Biol Chem. 2009; 284 (13):8738-46. doi: 10.1074/jbc.M808831200 PMID: 19103601; PubMed Central PMCID: PMC2659232.
45. Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor H binding. Clin Vaccine Immunol. 2010; 17 (7):1074-8. Epub 2010/06/04. CVI.00103-10 [pii] doi: 10.1128/CVI.00103-10 PMID: 20519444; PubMed Central PMCID: PMC2897264.